Business
Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion
Hengrui Pharma (600276.SH; 01276.HK) reported revenue of RMB23.20 billion for the first three quarters of 2025, up 14.85% year-on-year. Net profit attributable to shareholders was RMB5.75 billion, increased by 24.50% compared with the same period last year.
About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A
[{"type":"text","content":"SHANGHAI, Oct. 27, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK) reported revenue of RMB23.20 billion for the first three quarters of 2025, up 14.85% year-on-year. Net profit attributable to shareholders was RMB5.75 billion, increased by 24.50% compared with the same period last year.","length":297,"tagName":"p"},{"type":"text","content":"One NME was approved in China, while eight NDA submissions were made and 48 clinical trial approvals were granted during the period, with four programs admitted to breakthrough-therapy designation lists. The GLP-1/GIP dual agonist HRS9531 reported positive Phase III topline results in weight management, advancing one of the company's key late-stage metabolic assets.","length":372,"tagName":"p"},{"type":"text","content":"At ESMO 2025 in Berlin, Hengrui presented 46 oncology studies across 14 innovative programs — including nine oral presentations, one of which was published in The Lancet — marking its strongest presence to date at a major global cancer congress. In parallel, Hengrui signed three licensing deals with multinational partners in the third quarter, collectively exceeding US$10 billion in potential transaction value.","length":414,"tagName":"p"},{"type":"text","content":"Hengrui will remain focused on advancing its homegrown R&D innovation and strengthening global execution through clinical development and strategic partnerships to deliver more cutting-edge therapies to patients worldwide.","length":226,"tagName":"p"},{"type":"image","alt":"Cision","displaySize":"","headline":null,"caption":"Cision","className":"","disableSlideshowImg":false,"size":{"original":{"width":16,"height":16,"url":"https://media.zenfs.com/en/prnewswire.com/f4e6c6d405350e0b676850d5f59b2f1c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l1WA2P1OOS4OsoND3Qngkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2O2g9MzY7Y2Y9d2VicA--/https://media.zenfs.com/en/prnewswire.com/f4e6c6d405350e0b676850d5f59b2f1c","width":16,"height":16}}},{"type":"text","content":"View original content:https://www.prnewswire.com/news-releases/hengrui-pharma-reports-steady-growth-in-q3-2025-driven-by-innovation-and-global-expansion-302595258.html","length":167,"tagName":"p"}]
More updates from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A